Eisai to Divest Rights for Pariet in China to Peak Pharma
TOKYO, Apr 1, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet® (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. Peak Pharma has commenced marketing activities, while […]